• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肿瘤浸润调节性 T 细胞通过 PD-1 和抑制性受体的上调来界定。

Tumor-infiltrating regulatory T cells delineated by upregulation of PD-1 and inhibitory receptors.

机构信息

Department of Biochemistry, College of Life Science & Biotechnology, Yonsei University, Seoul 120-749, Republic of Korea.

出版信息

Cell Immunol. 2012 Jul-Aug;278(1-2):76-83. doi: 10.1016/j.cellimm.2012.07.001. Epub 2012 Jul 24.

DOI:10.1016/j.cellimm.2012.07.001
PMID:23121978
Abstract

Foxp3(+) regulatory T (T(reg)) cells are dominant suppressor cells which regulate conventional T (T(conv)) cells. Inside tumor microenvironment, T(reg) cells have been known to become potent in suppressing T(conv) cell responses, thereby enabling tumor cells to circumvent immune response. However, the underlying mechanism by which tumor-infiltrating T(reg) cells display enhanced suppressive function is still unresolved. To understand characteristics and function of tumor-infiltrating T(reg) cells as well as T(conv) cells in the tumor site, we analyzed their phenotypes either within tumor burden or at distant site of tumor using both heterotopic and orthotopic mouse cancer models. Compared to CD8(+) T cells at distant site of tumor, tumor-infiltrating CD8(+) T cells dramatically upregulated programmed death 1 (PD-1) and other inhibitory receptors, thereby being more exhausted functionally. Tumor-infiltrating CD4(+) T cells also expressed higher level of PD-1 than CD4(+) T cells at distant site of tumor but very surprisingly, upregulation of PD-1 occurred in CD4(+)Foxp3(+) T(reg) as well as CD4(+)Foxp3(-) T(conv) cells. Moreover, tumor infiltrating T(reg) cells upregulated other inhibitory receptors such as T cell immunoglobulin mucin 3 (TIM-3), cytotoxic T lymphocyte antigen-4 (CTLA-4), glucocorticoid-induced tumor necrosis factor receptor (GITR), and lymphocyte activation gene-3 (LAG-3). These results suggest that upregulation of PD-1 and other inhibitory receptors on tumor-infiltrating T(reg) cells is related with their enhanced suppressive function.

摘要

Foxp3(+) 调节性 T(T(reg))细胞是调节常规 T(T(conv))细胞的主要抑制性细胞。在肿瘤微环境中,T(reg)细胞已被证实能够有效地抑制 T(conv)细胞的反应,从而使肿瘤细胞能够逃避免疫反应。然而,肿瘤浸润 T(reg)细胞显示增强的抑制功能的潜在机制仍未解决。为了了解肿瘤部位浸润的 T(reg)细胞和 T(conv)细胞的特征和功能,我们使用异位和原位小鼠癌症模型分析了它们在肿瘤负荷内或远离肿瘤部位的表型。与远离肿瘤部位的 CD8(+) T 细胞相比,肿瘤浸润的 CD8(+) T 细胞显著上调程序性死亡受体 1(PD-1)和其他抑制性受体,从而在功能上更加衰竭。肿瘤浸润的 CD4(+) T 细胞也表达高于远离肿瘤部位的 CD4(+) T 细胞的 PD-1,但非常令人惊讶的是,PD-1 的上调发生在 CD4(+)Foxp3(+) T(reg)以及 CD4(+)Foxp3(-) T(conv)细胞中。此外,肿瘤浸润的 T(reg)细胞还上调了其他抑制性受体,如 T 细胞免疫球蛋白粘蛋白 3(TIM-3)、细胞毒性 T 淋巴细胞抗原-4(CTLA-4)、糖皮质激素诱导的肿瘤坏死因子受体(GITR)和淋巴细胞激活基因-3(LAG-3)。这些结果表明,PD-1 和其他抑制性受体在肿瘤浸润 T(reg)细胞上的上调与其增强的抑制功能有关。

相似文献

1
Tumor-infiltrating regulatory T cells delineated by upregulation of PD-1 and inhibitory receptors.肿瘤浸润调节性 T 细胞通过 PD-1 和抑制性受体的上调来界定。
Cell Immunol. 2012 Jul-Aug;278(1-2):76-83. doi: 10.1016/j.cellimm.2012.07.001. Epub 2012 Jul 24.
2
Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.针对免疫检查点分子的抗体恢复了肝癌浸润 T 细胞的功能。
Gastroenterology. 2017 Oct;153(4):1107-1119.e10. doi: 10.1053/j.gastro.2017.06.017. Epub 2017 Jun 23.
3
Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.PD-1 和 CTLA-4 的双重阻断联合肿瘤疫苗可有效恢复肿瘤中 T 细胞的排斥功能。
Cancer Res. 2013 Jun 15;73(12):3591-603. doi: 10.1158/0008-5472.CAN-12-4100. Epub 2013 Apr 30.
4
Treatment-enhanced CD4+Foxp3+ glucocorticoid-induced TNF receptor family related high regulatory tumor-infiltrating T cells limit the effectiveness of cytokine-based immunotherapy.治疗增强的CD4+Foxp3+糖皮质激素诱导的TNF受体家族相关高调节性肿瘤浸润T细胞限制了基于细胞因子的免疫疗法的有效性。
J Immunol. 2007 Mar 15;178(6):3400-8. doi: 10.4049/jimmunol.178.6.3400.
5
Novel Foxp3(-) IL-10(-) Regulatory T-cells Induced by B-Cells Alleviate Intestinal Inflammation in Vivo.B 细胞诱导产生的新型 Foxp3(-)IL-10(-)调节性 T 细胞可减轻体内肠道炎症。
Sci Rep. 2016 Sep 1;6:32415. doi: 10.1038/srep32415.
6
CD8 blockade promotes the expansion of antigen-specific CD4+ FOXP3+ regulatory T cells in vivo.CD8阻断可促进体内抗原特异性CD4+FOXP3+调节性T细胞的扩增。
Int Immunopharmacol. 2007 Feb;7(2):249-65. doi: 10.1016/j.intimp.2006.10.012. Epub 2006 Nov 28.
7
Neuropilin 1 deficiency on CD4+Foxp3+ regulatory T cells impairs mouse melanoma growth.CD4+Foxp3+ 调节性 T 细胞中神经纤毛蛋白 1 缺乏可抑制小鼠黑色素瘤生长。
J Exp Med. 2012 Oct 22;209(11):2001-16. doi: 10.1084/jem.20111497. Epub 2012 Oct 8.
8
HIV-1 binding to CD4 on CD4+CD25+ regulatory T cells enhances their suppressive function and induces them to home to, and accumulate in, peripheral and mucosal lymphoid tissues: an additional mechanism of immunosuppression.HIV-1与CD4+CD25+调节性T细胞上的CD4结合,增强其抑制功能,并诱导它们归巢至外周和黏膜淋巴组织并在其中积聚:一种额外的免疫抑制机制。
Int Immunol. 2009 Mar;21(3):283-94. doi: 10.1093/intimm/dxn146. Epub 2009 Feb 10.
9
Analysis of non-small cell lung cancer microenvironment indicates preponderance of T cell exhaustion marker expression.非小细胞肺癌微环境分析表明T细胞耗竭标志物表达占优势。
Exp Cell Res. 2017 Nov 15;360(2):205-209. doi: 10.1016/j.yexcr.2017.09.008. Epub 2017 Sep 8.
10
Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT.异基因造血干细胞移植后复发的 AML 患者骨髓中央记忆和记忆干细胞 T 细胞耗竭。
Nat Commun. 2019 Mar 25;10(1):1065. doi: 10.1038/s41467-019-08871-1.

引用本文的文献

1
Applications of mRNA Delivery in Cancer Immunotherapy.信使核糖核酸递送在癌症免疫治疗中的应用
Int J Nanomedicine. 2025 Mar 17;20:3339-3361. doi: 10.2147/IJN.S500520. eCollection 2025.
2
Immune signatures of patients with advanced non-small-cell lung cancer for efficacy prediction after immunotherapy.晚期非小细胞肺癌患者免疫治疗后疗效预测的免疫特征
Ther Adv Med Oncol. 2024 Oct 9;16:17588359241284946. doi: 10.1177/17588359241284946. eCollection 2024.
3
Promising immunotherapy targets: TIM3, LAG3, and TIGIT joined the party.
有前景的免疫治疗靶点:TIM3、LAG3和TIGIT也加入其中。
Mol Ther Oncol. 2024 Feb 12;32(1):200773. doi: 10.1016/j.omton.2024.200773. eCollection 2024 Mar 21.
4
Critical Roles of SRC-3 in the Development and Progression of Breast Cancer, Rendering It a Prospective Clinical Target.SRC-3在乳腺癌发生发展中的关键作用,使其成为一个有前景的临床靶点。
Cancers (Basel). 2023 Oct 31;15(21):5242. doi: 10.3390/cancers15215242.
5
Frequency of peripheral PD-1regulatory T cells is associated with treatment responses to PARP inhibitor maintenance in patients with epithelial ovarian cancer.外周 PD-1 调节性 T 细胞的频率与上皮性卵巢癌患者接受 PARP 抑制剂维持治疗的反应相关。
Br J Cancer. 2023 Nov;129(11):1841-1851. doi: 10.1038/s41416-023-02455-z. Epub 2023 Oct 11.
6
LAG-3 Inhibitors: Novel Immune Checkpoint Inhibitors Changing the Landscape of Immunotherapy.LAG-3抑制剂:改变免疫治疗格局的新型免疫检查点抑制剂。
Biomedicines. 2023 Jul 1;11(7):1878. doi: 10.3390/biomedicines11071878.
7
The long multi-epitope peptide vaccine combined with adjuvants improved the therapeutic effects in a glioblastoma mouse model.长多表位肽疫苗联合佐剂可提高胶质母细胞瘤小鼠模型的治疗效果。
Front Immunol. 2022 Nov 9;13:1007285. doi: 10.3389/fimmu.2022.1007285. eCollection 2022.
8
Effects of PD-1 Signaling on Immunometabolic Reprogramming.PD-1信号传导对免疫代谢重编程的影响。
Immunometabolism. 2022;4(2). doi: 10.20900/immunometab20220007. Epub 2022 Mar 10.
9
Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy.十年后的免疫检查点抑制剂:基础研究与临床应用在癌症免疫治疗中的贡献
Immune Netw. 2022 Feb 14;22(1):e2. doi: 10.4110/in.2022.22.e2. eCollection 2022 Feb.
10
Differential Role of PD-1 Expressed by Various Immune and Tumor Cells in the Tumor Immune Microenvironment: Expression, Function, Therapeutic Efficacy, and Resistance to Cancer Immunotherapy.肿瘤免疫微环境中各种免疫细胞和肿瘤细胞表达的PD-1的差异作用:表达、功能、治疗效果及对癌症免疫治疗的抗性
Front Cell Dev Biol. 2021 Nov 22;9:767466. doi: 10.3389/fcell.2021.767466. eCollection 2021.